Kangzhe Pharmaceutical (00867.HK) signed a cooperation agreement with Zhixiang Jintai on the exclusive distributing rights of KDY-001 monoclonal antibody injection and Slivami monoclonal antibody injection.

Zhitong Finance and Economics APP News, Kangzhe Pharmaceutical (00867.HK) announced on September 22, 2025, the group signed exclusive cooperation agreements with Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. (Zhixiang Jintai) through its subsidiary companies for the Class 1 therapeutic biological product Vimokdatumab monoclonal antibody injection (GR2001) for passive immunization indications for tetanus and the Class 1 therapeutic biological product Selvamimab monoclonal antibody injection (GR1801) for passive immunization indications for suspected exposure to rabies virus.